Authors: Rajagopalan Geetha Mutulur Krishnamoorthy Radika Emayavaramban Priyadarshini Krishnamurthy Bhavani Carani Venkatraman Anuradha
Publish Date: 2015/06/16
Volume: 407, Issue: 1-2, Pages: 263-279
Abstract
A previous study from our laboratory showed that troxerutin TX provides cardioprotection by mitigating lipid abnormalities in a highfat highfructose diet HFFDfed mice model of metabolic syndrome MS The present study aims to investigate the reversal effect of TX on the fibrogenic changes in the myocardium of HFFDfed mice Adult male Mus musculus mice were grouped into four and fed either control diet or HFFD for 60 days Each group was divided into two and the mice were either treated or untreated with TX 150 mg/kg bw po from the 16th day HFFDfed mice showed marked changes in the electrocardiographic data Increased levels of myocardial superoxide p22phox subunit of NADPH oxidase transforming growth factor TGF smooth muscle actin αSMA and matrix metalloproteinases MMPs9 and 2 and decreased levels of tissue inhibitors of MMPs1 and 2 were observed Furthermore degradation products of troponin I and myosin light chain1 were observed in the myocardium by immunoblotting Rise in collagen was observed by hydroxyproline assay while fibrotic changes were noticed by histology and Western blotting Hypertrophy of cardiomyocytes and myocardial calcium accumulation were also observed in HFFDfed mice TX treatment exerted cardioprotective and antifibrotic effects in HFFDfed mice by improving cardiac contractile function reducing superoxide production and by favorably modifying the fibrosis markers These findings suggest that TX could be cardioprotective through its antioxidant and antifibrogenic actions This new finding could pave way for translation studies to human MS
Keywords: